“This is where I believe my insight can be valuable... We were never going to get uplisted or approved for anything until a vaccine was rolled out.”

This is the most ridiculous post I’ve read on IH in sometime. Leronlimab was never going to be approved without full enrollment or near perfect interim analysis data. NP didn’t focus on S/C enrollment because he expected approval at the 50% interim analysis and due to competition with other treatments. Even if leronlimab was approved in July, the world would still need a vaccine.